Yedida Y Bogachkov PhD,  —

Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews.

Articles by Yedida Y Bogachkov PhD

MJFF Awards 2 Bachmann-Strauss Fellowships in Dystonia Research

A new training program, the Bachmann-Strauss Fellowship in Dystonia Research aims to grow the number of researchers focused on the movement disorder known as dystonia. Launched by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the fellowship will support specialized training for those dedicated to investigating the causes…

Phase 2 Trial of Oral Oligomannate Will Target Gut-Brain Axis

Green Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in people with early-stage Parkinson’s disease, according to a press release. This follows the acceptance of Green Valley‘s investigational new drug (IND) application by the U.S Food and Drug…

Sanofi, ABL Bio Join to Develop ABL301 as Potential Treatment

ABL Bio and Sanofi are working under a global licensing agreement to jointly develop ABL301 — an investigational bispecific antibody targeting both alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) — in possibly treating Parkinson’s disease. Under the agreement, ABL Bio will lead further preclinical testing and a…

MJFF Grant Supports Work Into Potential of Sigma-2 Receptors

Cognition Therapeutics has received a grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to support preclinical work into two potential sigma-2 receptor modulators for Parkinson’s disease. The Therapeutic Pipeline Program Grant award, whose amount and duration were not specified, will help to fund studies of these…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums